Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis — Christopher Em Griffiths (2016) | RDL Network
Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis
Continuous tofacitinib treatment provided sustained improvement in HRQoL and disease symptoms. Patients randomized to treatment withdrawal lost initial improvements. Upon re-treatment, improvements were recaptured to levels comparable to those seen with continuous treatment.
Robert Bissonnette, Lars Iversen, Howard Sofen, Christopher Em Griffiths, Peter Foley, Ricardo Romiti, Mary Bachinsky, S.T. Rottinghaus, Huaming Tan, James Proulx, Hernán Valdez, Pankaj Gupta, Lotus Mallbris, Robert Wołk
H. Bachelez, Christopher Em Griffiths, Kim Papp, Stephen Hall, Joseph F. Merola, Steven R. Feldman, Majed Khraishi, Huaming Tan, Lara Fallon, Joseph C. Cappelleri, Andrew G. Bushmakin, Pamela Young
Alessandra Tedeschi, Meletios A Dimopoulos, Judith Trotman, Ramón García‐Sánz, D. Blair Macdonald, Beatrice Mahé, Charles Herbaux, Leonard T. Heffner, Constantine S. Tam, Marzia Varettoni, M. Lia Palomba, J. Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, J. Li, Erik Poulsen, B. Hauns, Christian Buske, V. Leblond
Alessandra Tedeschi, Meletios A Dimopoulos, Judith Trotman, Ramón García‐Sánz, David MacDonald, Beatrice Mahé, Charles Herbaux, Leonard T. Heffner, Constantine S. Tam, Marzia Varettoni, Maria Lia Palomba, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Erik Poulsen, Bernhard Hauns, Christian Buske, Véronique Leblond
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.